Sean O’Hearen, 1st Line Partners

Companies must assess illicit trade risks under a new EU directive, making materiality and compliance critical for sustainability reporting.

Counterfeit drugs infiltrating the US pharma supply chain through gray market channels underscore the urgent need for vigilance.

Healthcare providers must enhance awareness of counterfeit medicines to protect patients, especially as online drug purchases rise.

Why taking proactive steps—and combing the right data sources—is critical to informed decision-making in risk management.

Introducing a new Pharma Commerce column focused on combating illicit trade and protecting product integrity—and ultimately patients.